Last reviewed · How we verify
OBE001
OBE001 is an oxytocin receptor antagonist that inhibits uterine contractions by blocking oxytocin signaling in myometrial smooth muscle.
OBE001 is a small-molecule oxytocin receptor antagonist developed by ObsEva SA for reproductive health indications, specifically preterm labor prevention and embryo transfer support in infertility. The drug works by blocking oxytocin signaling in uterine smooth muscle, thereby reducing uterine contractions and prolonging pregnancy or improving implantation conditions. Two Phase 2 trials were conducted: one in preterm labor (terminated early with N=10) and one in embryo transfer (completed with N=247), but the program was ultimately discontinued, indicating insufficient efficacy or commercial viability. OBE001 represented a non-oral formulation approach to tocolysis, differentiating it from oral agents but facing challenges in clinical development. The drug never reached regulatory approval or commercial launch. ObsEva SA reported $20M revenue in 2022, but OBE001 did not contribute meaningfully to the company's commercial portfolio.
At a glance
| Generic name | OBE001 |
|---|---|
| Sponsor | ObsEva SA |
| Drug class | Oxytocin receptor antagonist; Tocolytic agent |
| Target | Oxytocin receptor (OXTR) |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | discontinued |
Mechanism of action
OBE001 works by antagonizing the oxytocin receptor, a G-protein coupled receptor expressed on uterine smooth muscle cells. Oxytocin is the natural hormone responsible for triggering uterine contractions during labor. By blocking this receptor, OBE001 suppresses spontaneous and induced myometrial contractions, thereby delaying or preventing preterm labor. In the context of assisted reproduction, the same mechanism may reduce uterine contractility during embryo transfer, potentially improving implantation rates by creating a more quiescent uterine environment. The drug was designed as a non-oral tocolytic agent, offering an alternative to existing oral or intravenous options.
Approved indications
Pipeline indications
- Preterm labor (delay of preterm birth) — Phase 2
- Infertility (embryo transfer support) — Phase 2
Common side effects
Drug interactions
- Betamethasone
Key clinical trials
- A Phase 2 Study of OBE001 Versus Placebo in the Delay of Preterm Birth (PHASE2)
- OBE001 Phase 2 Dose-finding Study Versus Placebo in Women Undergoing Embryo Transfer in the Context of IVF-ICSI (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OBE001 CI brief — competitive landscape report
- OBE001 updates RSS · CI watch RSS
- ObsEva SA portfolio CI